GLP-1 axis influences adipose tissue plasticity and lipoprotein metabolism beyond weight loss, reducing cardiovascular risk

The global burden of obesity and its associated cardiometabolic sequelae remains a critical public health challenge. Current standard-of-care interventions, including diet and exercise, often yield modest and unsustainable results, particularly for populations like those with spinal cord injury (SCI) who face disproportionate risk. While GLP-1 receptor (GLP-1R) agonists have revolutionized obesity management through significant weight reduction, emerging evidence suggests their cardioprotective effects extend beyond mere adiposity loss. A deeper understanding of these weight-independent mechanisms, particularly concerning lipoprotein metabolism and adipose tissue plasticity, is crucial to fully harness the therapeutic potential of the GLP-1 axis.

This comprehensive review synthesized existing literature to elucidate the multifaceted roles of the GLP-1 axis in cardiovascular risk reduction. The authors systematically examined both weight-dependent and weight-independent mechanisms by which GLP-1R agonists influence cardiometabolic health. A particular focus was placed on their impact on lipoprotein metabolism and the modulation of adipose tissue plasticity. The review aimed to identify how these agents exert favorable effects on postprandial lipoprotein metabolism and enhance adipose tissue function, ultimately proposing a framework for expanding their clinical application.

The review highlighted that the GLP-1 axis is a pleiotropic regulator of cardiometabolic health, with its therapeutic potential extending significantly beyond weight loss. GLP-1R agonists were shown to exert favorable effects on postprandial lipoprotein metabolism, a key factor in cardiovascular disease progression. Furthermore, the synthesis of evidence demonstrated that these agents influence adipose tissue function and promote beneficial adipose tissue plasticity, contributing to enhanced metabolic health. These effects include improved insulin sensitivity, reduced inflammation, and favorable changes in lipid profiles, which collectively contribute to a reduction in cardiovascular risk. The authors concluded that the cardioprotective benefits of GLP-1R agonists are not solely attributable to weight reduction but also involve direct modulation of metabolic pathways and tissue function. This comprehensive understanding underscores the GLP-1 axis as a critical target for broader cardiovascular risk reduction strategies. > The review emphasizes that GLP-1R agonists' cardioprotective effects transcend adiposity reduction, involving direct modulation of lipoprotein metabolism and adipose tissue function.